The average age of menopause is 51. The women whose data produced the warning that has shaped hormone therapy for 24 years were, on average, 63. That is a 12-year gap, and it is the whole story. It took until this February for a regulator to say so in writing, when the FDA formally approved removing the black-box warning, its strongest safety label, from six menopausal hormone therapy (MHT) products.
The warning traces to one trial. In July 2002, the combined-hormone arm of the Women's Health Initiative was stopped five years in, after a monitoring board found its risks had overtaken its benefits. Its 16,608 participants averaged 63 years old, and a later review of the trial found they were, on average, roughly ten years past menopause, with only one in six within five years of it, the point at which most women actually decide whether to start treatment. They were also taking Prempro, an oral combination of conjugated equine estrogen and synthetic progestin. A later clinical review of hormone therapy noted that the transdermal, lower-dose formulations more common today work differently in the body: "transdermal and topical estrogens bypass first pass metabolism so can be dosed lower than oral estrogen," with "less impact on triglycerides, coagulation factors and gallbladder disease," and, unlike the oral estrogen used in the WHI trial, are unlikely to raise clotting risk the same way.
The risk increases that made headlines were real, not fabricated, and modest, not the crisis the headlines made of it. Breast cancer risk rose 26 percent, coronary heart disease risk rose 29 percent, and stroke risk rose 41 percent, while blood clot risk roughly doubled.
Put in absolute terms, the numbers shrink further. The original 2002 JAMA paper reported that over one year, 10,000 women taking the therapy would see about 7 more heart events, 8 more strokes, 18 more blood clots, and 8 more invasive breast cancers than 10,000 women on a placebo, against 6 fewer colorectal cancers and 5 fewer hip fractures. Those are small numbers to have built a two-decade blanket warning on, and they came from a trial concentrated in women a decade past the age the FDA now says matters most.
Use never really recovered in the meantime. A Mayo Clinic Proceedings study led by Dr. Stephanie Faubion tracked hormone therapy use among insured American women 40 and older from 2007 to 2023 and found it fall from 4.4 percent to 1.7 percent. Even in the 50-to-59 age band, the group current guidance most favors for starting treatment, use dropped from 7.1 percent to 3.5 percent over the same years, and use was consistently lower among Black, Hispanic, and Asian American women than among white women throughout. Faubion's study did not set out to explain that gap, but I have read enough explanation-of-benefits letters in my own reporting to recognize one plausible pattern: a step-therapy rule, an insurer's requirement that a patient try and fail a cheaper option first, is exactly the kind of quiet gatekeeping that can keep a modest, overstated risk shaping care for decades. It is the kind of pattern the FDA itself would later call a distortion, in the word it used when it announced the reversal. Faubion's team expected the numbers to rebound as menopause got talked about more openly. They had not, at least not by 2023. "We have strong evidence that hormone therapy is safe and effective for many women," she said, "but that hasn't translated into how it's used in clinical practice."
The correction arrived in two steps. In November 2025, the FDA announced it would begin stripping the black-box warning from MHT labels, and by February 12, 2026, it had formally approved the change for the first six products, spanning four hormone-therapy categories: three systemic estrogen-alone therapies, and one product each in the combination-therapy, progesterone-only, and vaginal-estrogen categories. Gone from the boxed warning: the blanket cardiovascular disease, breast cancer, and "probable dementia" statements. Left in place: the endometrial cancer warning on estrogen-alone products for women who still have a uterus, since unopposed estrogen, estrogen taken without a progestin to protect the uterine lining, genuinely does raise that risk. FDA Commissioner Marty Makary framed the reversal bluntly: "tens of millions of women have been denied the life-changing and long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk."
The new label leans on what researchers call the critical window, or timing, hypothesis: that estrogen's effects on the heart and brain depend on how soon after menopause it starts, generally within ten years or before age 60. Started in that window, reanalysis of the WHI data points to lower cardiovascular and fracture risk; started well past it, the same hormone shows neutral or harmful associations. No trial has tested this timing question with a randomized design, and it is worth saying plainly why: Rachel Whitmer, a Kaiser Permanente researcher who has studied the hypothesis, and her coauthors wrote in the Annals of Neurology that such a trial "is unfeasible, if not impossible," since the WHI results already established that starting hormone therapy late in life carries real stroke and cancer risk, making it unethical to randomize older women to it again just to test the timing. The label change rests on the best available reanalysis, not on a new definitive trial.
Prescribing has already surged since the FDA's November announcement. Truveta, a health-data analytics firm that tracks real-world prescribing records, found estrogen-based hormone therapy prescribing up 19 percent between July 2025 and February 2026, with women 45 to 54 reaching rates 184 percent higher than in 2018. A separate analysis by Epic Research, a firm that works from the same kind of insurance claims data, put the rise at 72 to 86 percent since 2021. NBC News reported that national prescriptions of estradiol, the estrogen most commonly prescribed today, climbed from around 18 million in 2021 to nearly 32 million in the most recent year counted, a run so fast that the estrogen patch, one of the most commonly insured delivery forms, landed on the American Society of Health-System Pharmacists' national drug shortage list at the end of January.
That is the tension worth naming honestly, and clinicians are already naming it. "The removal of the black box lowers a barrier to appropriate care and reflects evolving evidence," Dr. Jessica Chan, a reproductive endocrinologist at Cedars-Sinai, told her hospital's own publication, "but it does not mean MHT is right for every woman in perimenopause or menopause." She was specific about where the new optimism should stop: "Hormones are not a treatment for dementia." Her colleague Dr. Sharon Winer, quoted in the same publication, added a similar caution about the heart: "There's no data to suggest that MHT prevents heart disease." A generation of women was told to fear a treatment many of them should have been offered. The correction to that is not a new blanket message in the other direction. It is the same thing it always should have been: a prescription drug, dosed and timed for the person taking it, not for the trial that happened to get run first.
